Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

AXL Is a Novel Predictive Factor and Therapeutic Target for Radioactive Iodine Refractory Thyroid Cancer.

Collina F, La Sala L, Liotti F, Prevete N, La Mantia E, Chiofalo MG, Aquino G, Arenare L, Cantile M, Liguori G, Di Gennaro F, Pezzullo L, Losito NS, Vecchio G, Botti G, Melillo RM, Franco R.

Cancers (Basel). 2019 Jun 7;11(6). pii: E785. doi: 10.3390/cancers11060785.

2.

Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies.

Liotti F, Prevete N, Vecchio G, Melillo RM.

F1000Res. 2019 Feb 28;8. pii: F1000 Faculty Rev-227. doi: 10.12688/f1000research.16677.1. eCollection 2019. Review.

3.

Retraction: The Receptor-Type Protein Tyrosine Phosphatase J Antagonizes the Biochemical and Biological Effects of RET-Derived Oncoproteins.

Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A.

Cancer Res. 2018 Dec 15;78(24):6907. doi: 10.1158/0008-5472.CAN-18-3456. No abstract available.

PMID:
30552125
4.

Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer.

Paladino S, Melillo RM.

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx106. No abstract available.

PMID:
30053081
5.

Role of Formyl Peptide Receptors in Gastrointestinal Healing.

Prevete N, de Paulis A, Sgambato D, Melillo RM, D Argenio G, Romano L, Zagari RM, Romano M.

Curr Pharm Des. 2018;24(18):1966-1971. doi: 10.2174/1381612824666180516102234.

PMID:
29766783
6.

Retraction for Melillo et al., "Critical Role of the HMGI(Y) Proteins in Adipocytic Cell Growth and Differentiation".

Melillo RM, Pierantoni GM, Scala S, Battista S, Fedele M, Stella A, De Biasio MC, Chiappetta G, Fidanza V, Condorelli G, Santoro M, Croce CM, Viglietto G, Fusco A.

Mol Cell Biol. 2018 Feb 27;38(6). pii: e00660-17. doi: 10.1128/MCB.00660-17. Print 2018 Mar 15. No abstract available.

7.

New perspectives in cancer: Modulation of lipid metabolism and inflammation resolution.

Prevete N, Liotti F, Amoresano A, Pucci P, de Paulis A, Melillo RM.

Pharmacol Res. 2018 Feb;128:80-87. doi: 10.1016/j.phrs.2017.09.024. Epub 2017 Oct 3. Review.

PMID:
28986132
8.

RET-mediated modulation of tumor microenvironment and immune response in multiple endocrine neoplasia type 2 (MEN2).

Castellone MD, Melillo RM.

Endocr Relat Cancer. 2018 Feb;25(2):T105-T119. doi: 10.1530/ERC-17-0303. Epub 2017 Sep 20. Review.

PMID:
28931560
9.

Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways.

Prevete N, Liotti F, Illiano A, Amoresano A, Pucci P, de Paulis A, Melillo RM.

Oncoimmunology. 2017 Feb 21;6(4):e1293213. doi: 10.1080/2162402X.2017.1293213. eCollection 2017.

10.

Multiple anti-tumor effects of Reparixin on thyroid cancer.

Liotti F, De Pizzol M, Allegretti M, Prevete N, Melillo RM.

Oncotarget. 2017 May 30;8(22):35946-35961. doi: 10.18632/oncotarget.16412.

11.

Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1.

Moretti S, Menicali E, Nucci N, Voce P, Colella R, Melillo RM, Liotti F, Morelli S, Fallarino F, Macchiarulo A, Santoro M, Avenia N, Puxeddu E.

J Biol Chem. 2017 Feb 3;292(5):1785-1797. doi: 10.1074/jbc.M116.745448. Epub 2016 Dec 19.

12.

Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.

Liotti F, Collina F, Pone E, La Sala L, Franco R, Prevete N, Melillo RM.

Stem Cells. 2017 Jan;35(1):135-146. doi: 10.1002/stem.2492. Epub 2016 Sep 21.

13.

Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth.

Prevete N, Liotti F, Marone G, Melillo RM, de Paulis A.

Pharmacol Res. 2015 Dec;102:184-91. doi: 10.1016/j.phrs.2015.09.017. Epub 2015 Oct 20. Review.

PMID:
26466865
14.

AXL is an oncotarget in human colorectal cancer.

Martinelli E, Martini G, Cardone C, Troiani T, Liguori G, Vitagliano D, Napolitano S, Morgillo F, Rinaldi B, Melillo RM, Liotti F, Nappi A, Bianco R, Berrino L, Ciuffreda LP, Ciardiello D, Iaffaioli V, Botti G, Ferraiolo F, Ciardiello F.

Oncotarget. 2015 Sep 15;6(27):23281-96.

15.

Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway.

Visciano C, Liotti F, Prevete N, Cali' G, Franco R, Collina F, de Paulis A, Marone G, Santoro M, Melillo RM.

Oncogene. 2015 Oct 1;34(40):5175-86. doi: 10.1038/onc.2014.441. Epub 2015 Jan 26.

PMID:
25619830
16.

Genetics: The genomic landscape of papillary thyroid carcinoma.

Santoro M, Melillo RM.

Nat Rev Endocrinol. 2015 Mar;11(3):133-4. doi: 10.1038/nrendo.2014.209. Epub 2014 Nov 25. No abstract available.

PMID:
25421371
17.

The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.

Prevete N, Liotti F, Visciano C, Marone G, Melillo RM, de Paulis A.

Oncogene. 2015 Jul;34(29):3826-38. doi: 10.1038/onc.2014.309. Epub 2014 Sep 29.

PMID:
25263443
18.

Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation.

Esposito F, Pierantoni GM, Battista S, Melillo RM, Scala S, Chieffi P, Fedele M, Fusco A.

J Biol Chem. 2014 Jun 20;289(25):17425. doi: 10.1074/jbc.A109.034280.

19.

Indoleamine 2,3-dioxygenase 1 (IDO1) is up-regulated in thyroid carcinoma and drives the development of an immunosuppressant tumor microenvironment.

Moretti S, Menicali E, Voce P, Morelli S, Cantarelli S, Sponziello M, Colella R, Fallarino F, Orabona C, Alunno A, de Biase D, Bini V, Mameli MG, Filetti S, Gerli R, Macchiarulo A, Melillo RM, Tallini G, Santoro M, Puccetti P, Avenia N, Puxeddu E.

J Clin Endocrinol Metab. 2014 May;99(5):E832-40. doi: 10.1210/jc.2013-3351. Epub 2014 Feb 11.

PMID:
24517146
20.

Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.

Krishnamoorthy GP, Guida T, Alfano L, Avilla E, Santoro M, Carlomagno F, Melillo RM.

J Biol Chem. 2013 Jun 14;288(24):17481-94. doi: 10.1074/jbc.M112.439422. Epub 2013 Apr 29.

21.

Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension.

Carlomagno G, Messalli G, Melillo RM, Stanziola AA, Visciano C, Mercurio V, Imbriaco M, Ghio S, Sofia M, Bonaduce D, Fazio S.

Int J Cardiol. 2013 Sep 30;168(2):1545-7. doi: 10.1016/j.ijcard.2012.12.031. Epub 2013 Jan 3. No abstract available.

PMID:
23290950
22.

Molecular biomarkers in thyroid FNA samples.

Melillo RM, Santoro M.

J Clin Endocrinol Metab. 2012 Dec;97(12):4370-3. doi: 10.1210/jc.2012-3730. No abstract available.

PMID:
23223485
23.

Inflammation in thyroid oncogenesis.

Liotti F, Visciano C, Melillo RM.

Am J Cancer Res. 2012;2(3):286-97. Epub 2012 Apr 21.

24.

Higher intratumoral expression of CD1a, tryptase, and CD68 in a follicular variant of papillary thyroid carcinoma compared to adenomas: correlation with clinical and pathological parameters.

Proietti A, Ugolini C, Melillo RM, Crisman G, Elisei R, Santoro M, Minuto M, Vitti P, Miccoli P, Basolo F.

Thyroid. 2011 Nov;21(11):1209-15. doi: 10.1089/thy.2011.0059. Epub 2011 Oct 18.

PMID:
22007938
25.

CXCR4 expression correlates with the degree of tumor infiltration and BRAF status in papillary thyroid carcinomas.

Torregrossa L, Giannini R, Borrelli N, Sensi E, Melillo RM, Leocata P, Materazzi G, Miccoli P, Santoro M, Basolo F.

Mod Pathol. 2012 Jan;25(1):46-55. doi: 10.1038/modpathol.2011.140. Epub 2011 Sep 9.

26.

Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer.

Avilla E, Guarino V, Visciano C, Liotti F, Svelto M, Krishnamoorthy G, Franco R, Melillo RM.

Cancer Res. 2011 Mar 1;71(5):1792-804. doi: 10.1158/0008-5472.CAN-10-2186. Epub 2011 Feb 22.

27.
28.

Mast cells have a protumorigenic role in human thyroid cancer.

Melillo RM, Guarino V, Avilla E, Galdiero MR, Liotti F, Prevete N, Rossi FW, Basolo F, Ugolini C, de Paulis A, Santoro M, Marone G.

Oncogene. 2010 Nov 25;29(47):6203-15. doi: 10.1038/onc.2010.348. Epub 2010 Aug 23.

PMID:
20729915
29.

CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1.

Torregrossa L, Faviana P, Filice ME, Materazzi G, Miccoli P, Vitti P, Fontanini G, Melillo RM, Santoro M, Basolo F.

Thyroid. 2010 May;20(5):495-504. doi: 10.1089/thy.2009.0282.

PMID:
20450430
30.

Thyroid cancer and inflammation.

Guarino V, Castellone MD, Avilla E, Melillo RM.

Mol Cell Endocrinol. 2010 May 28;321(1):94-102. doi: 10.1016/j.mce.2009.10.003. Epub 2009 Oct 14. Review.

PMID:
19835928
31.

Helicobacter pylori Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo.

de Paulis A, Prevete N, Rossi FW, Rivellese F, Salerno F, Delfino G, Liccardo B, Avilla E, Montuori N, Mascolo M, Staibano S, Melillo RM, D'Argenio G, Ricci V, Romano M, Marone G.

J Immunol. 2009 Sep 15;183(6):3761-9. doi: 10.4049/jimmunol.0900863. Epub 2009 Aug 19.

32.

Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation.

Esposito F, Pierantoni GM, Battista S, Melillo RM, Scala S, Chieffi P, Fedele M, Fusco A.

J Biol Chem. 2009 Sep 18;284(38):25993-6004. doi: 10.1074/jbc.M109.034280. Epub 2009 Jul 26. Retraction in: J Biol Chem. 2014 Jun 20;289(25):17425.

33.

XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.

Lodyga M, De Falco V, Bai XH, Kapus A, Melillo RM, Santoro M, Liu M.

Oncogene. 2009 Feb 19;28(7):937-49. doi: 10.1038/onc.2008.447. Epub 2008 Dec 8.

PMID:
19060924
34.

A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.

Fazioli F, Piccinini G, Appolloni G, Bacchiocchi R, Palmonella G, Recchioni R, Pierpaoli E, Silvetti F, Scarpelli M, Bruglia M, Melillo RM, Santoro M, Boscaro M, Taccaliti A.

Thyroid. 2008 Jul;18(7):775-82. doi: 10.1089/thy.2007.0365.

PMID:
18631007
35.

Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer.

De Falco V, Guarino V, Avilla E, Castellone MD, Salerno P, Salvatore G, Faviana P, Basolo F, Santoro M, Melillo RM.

Cancer Res. 2007 Dec 15;67(24):11821-9.

36.

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome.

Staibano S, Merolla F, Testa D, Iovine R, Mascolo M, Guarino V, Castellone MD, Di Benedetto M, Galli V, Motta S, Melillo RM, De Rosa G, Santoro M, Celetti A.

Br J Cancer. 2007 Dec 3;97(11):1545-51. Epub 2007 Nov 6.

37.

A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma.

Salvatore G, Nappi TC, Salerno P, Jiang Y, Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici AM, Melillo RM, Fusco A, Bittner ML, Santoro M.

Cancer Res. 2007 Nov 1;67(21):10148-58.

38.

Receptor- and non-receptor tyrosine kinases induce processing of the amyloid precursor protein: role of the low-density lipoprotein receptor-related protein.

Minopoli G, Passaro F, Aloia L, Carlomagno F, Melillo RM, Santoro M, Forzati F, Zambrano N, Russo T.

Neurodegener Dis. 2007;4(2-3):94-100.

PMID:
17596703
39.

RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.

De Falco V, Castellone MD, De Vita G, Cirafici AM, Hershman JM, Guerrero C, Fusco A, Melillo RM, Santoro M.

Cancer Res. 2007 Jan 1;67(1):381-90.

40.

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

Santoro M, Melillo RM, Fusco A.

Eur J Endocrinol. 2006 Nov;155(5):645-53.

PMID:
17062879
41.

Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.

Vitagliano D, Portella G, Troncone G, Francione A, Rossi C, Bruno A, Giorgini A, Coluzzi S, Nappi TC, Rothstein JL, Pasquinelli R, Chiappetta G, Terracciano D, Macchia V, Melillo RM, Fusco A, Santoro M.

Oncogene. 2006 Aug 31;25(39):5467-74. Epub 2006 Jun 19.

PMID:
16785999
42.

The receptor-type protein tyrosine phosphatase J antagonizes the biochemical and biological effects of RET-derived oncoproteins.

Iervolino A, Iuliano R, Trapasso F, Viglietto G, Melillo RM, Carlomagno F, Santoro M, Fusco A.

Cancer Res. 2006 Jun 15;66(12):6280-7. Retraction in: Cancer Res. 2018 Dec 15;78(24):6907.

43.

HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.

Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, Helin K, Croce CM, Fusco A.

Cancer Cell. 2006 Jun;9(6):459-71.

44.

BRAF is a therapeutic target in aggressive thyroid carcinoma.

Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M.

Clin Cancer Res. 2006 Mar 1;12(5):1623-9.

45.

Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.

Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, Tartaglia M, Santoro M, Puxeddu E.

Oncogene. 2006 Jul 13;25(30):4235-40. Epub 2006 Feb 27.

PMID:
16501605
46.

Activation of the Erk8 mitogen-activated protein (MAP) kinase by RET/PTC3, a constitutively active form of the RET proto-oncogene.

Iavarone C, Acunzo M, Carlomagno F, Catania A, Melillo RM, Carlomagno SM, Santoro M, Chiariello M.

J Biol Chem. 2006 Apr 14;281(15):10567-76. Epub 2006 Feb 16.

47.

Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness.

Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, Mansueto G, Somma P, De Rosa G, Galli V, Melillo RM, Santoro M.

Clin Cancer Res. 2005 Nov 15;11(22):8019-27.

48.

Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness.

Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M.

J Clin Endocrinol Metab. 2005 Sep;90(9):5270-8. Epub 2005 Jul 5.

PMID:
15998773
49.

RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors.

De Falco V, Guarino V, Malorni L, Cirafici AM, Troglio F, Erreni M, Pelicci G, Santoro M, Melillo RM.

Oncogene. 2005 Sep 15;24(41):6303-13.

PMID:
15940252
50.

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M.

J Clin Invest. 2005 Apr;115(4):1068-81. Epub 2005 Mar 10. Retraction in: J Clin Invest. 2016 Apr 1;126(4):1603.

Supplemental Content

Loading ...
Support Center